Trials / Completed
CompletedNCT00985166
A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
Administration of Frozen Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine to Healthy Children at 4 to 6 Years of Age
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 801 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 4 Years – 6 Years
- Healthy volunteers
- Accepted
Summary
The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live) | A Single 0.5 mL subcutaneous injection at Day 1 |
| BIOLOGICAL | Comparator: M-M-R II | A Single 0.5 mL subcutaneous injection at Day 1 |
| BIOLOGICAL | Comparator: Varivax | A Single 0.5 mL subcutaneous injection at Day 1 |
| BIOLOGICAL | Comparator: Placebo | A Single 0.5 mL subcutaneous placebo injection at Day 1 |
Timeline
- Start date
- 2000-08-01
- Primary completion
- 2002-05-01
- Completion
- 2003-05-01
- First posted
- 2009-09-28
- Last updated
- 2015-07-28
- Results posted
- 2010-01-29
Source: ClinicalTrials.gov record NCT00985166. Inclusion in this directory is not an endorsement.